FM
KDNY

Frazier Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Frazier Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,371,918
Closed -$38.7M – 36
2021
Q4 		$38.7M Buy
2,371,918
+700,000
+42% +$9.96M 2.98% 11
2021
Q3 		$21.3M Buy
1,671,918
+571,918
+52% +$7.53M 1.71% 19
2021
Q2 		$15.5M Buy
+1,100,000
New +$17.6M 1.43% 16

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Frazier Management's KDNY Position: Q1 2022 in Review

Frazier Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2022, closing a stake of 2,371,918 shares — an estimated $38.7M sold.

Frazier Management first reported a position in KDNY in Q2 2021 and held it in 3 quarters. The position peaked at $38.7M in Q4 2021. 105 funds tracked by Wall St. Rank hold KDNY as of Q1 2022.

  • Frazier Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 2,371,918 Chinook Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $38.7M.
  • Frazier Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Frazier Management's Chinook Therapeutics, Inc. Common Stock position peaked at $38.7M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.